Drug Profile
Hydroxocobalamin - Research Corporation Technologies
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Research Corporation Technologies
- Class Corrinoids; Vitamin B12 analogues; Vitamins
- Mechanism of Action Nitric oxide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Septic shock
Most Recent Events
- 23 Feb 2004 Discontinued - Preclinical for Septic shock in USA (Parenteral)
- 14 Jul 1998 No-Development-Reported for Septic shock in USA (Parenteral)
- 02 Aug 1995 New profile